Literature DB >> 20554028

Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE.

Rina Aharoni1, Raya Eilam, Ariel Stock, Anya Vainshtein, Elias Shezen, Hilah Gal, Nir Friedman, Ruth Arnon.   

Abstract

The aim of this study was to identify cell populations relevant to pathogenesis and repair within the injured CNS in mice that recovered from experimental autoimmune encephalomyelitis (EAE). We demonstrate that in two EAE models, with either relapsing-remitting or chronic course, T-cells and resident activated microglia manifested extensive IL-17 expression, with apparent localization within regions of myelin loss. In mice treated with glatiramer acetate (GA, Copaxone), even when treatment started after disease exacerbation, CNS inflammation and Th-17 occurrence were drastically reduced, with parallel elevation in T-regulatory cells, indicating the immunomodulatory therapeutic consequences of GA treatment in situ. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20554028     DOI: 10.1016/j.jneuroim.2010.04.022

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  25 in total

1.  Immunoregulation of Theiler's virus-induced demyelinating disease by glatiramer acetate without suppression of antiviral immune responses.

Authors:  Seiichi Omura; Fumitaka Sato; Nicholas E Martinez; Tierra Range; Lesya Ekshyyan; Alireza Minagar; J Steven Alexander; Ikuo Tsunoda
Journal:  Arch Virol       Date:  2018-01-23       Impact factor: 2.574

Review 2.  Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies.

Authors:  Elena Grebenciucova; Amy Pruitt
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09-22       Impact factor: 5.081

3.  The strategies used for treatment of experimental autoimmune neuritis (EAN): a beneficial effect of glatiramer acetate administered intraperitoneally.

Authors:  Ramona Aronovich; Aviva Katzav; Joab Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

Review 4.  The development of myelin repair agents for treatment of multiple sclerosis: progress and challenges.

Authors:  Robert P Murphy; Keith J Murphy; Mark Pickering
Journal:  Bioengineered       Date:  2012-11-12       Impact factor: 3.269

Review 5.  The Evolving Mechanisms of Action of Glatiramer Acetate.

Authors:  Thomas Prod'homme; Scott S Zamvil
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

6.  Glatiramer acetate for treatment of MS: regulatory B cells join the cast of players.

Authors:  Luc Van Kaer
Journal:  Exp Neurol       Date:  2010-10-20       Impact factor: 5.330

Review 7.  Pathways towards an effective immunotherapy for Parkinson's disease.

Authors:  Jessica A L Hutter-Saunders; Rodney Lee Mosley; Howard E Gendelman
Journal:  Expert Rev Neurother       Date:  2011-12       Impact factor: 4.618

Review 8.  Biomaterial strategies for generating therapeutic immune responses.

Authors:  Sean H Kelly; Lucas S Shores; Nicole L Votaw; Joel H Collier
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

9.  Randomized peptide assemblies for enhancing immune responses to nanomaterials.

Authors:  Nicole L Votaw; Lauren Collier; Elizabeth J Curvino; Yaoying Wu; Chelsea N Fries; Madison T Ojeda; Joel H Collier
Journal:  Biomaterials       Date:  2021-04-15       Impact factor: 15.304

Review 10.  What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?

Authors:  Katherine A Buzzard; Simon A Broadley; Helmut Butzkueven
Journal:  Int J Mol Sci       Date:  2012-10-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.